AnaptysBio's collaboration revenue significantly increased to $30.0 million in Q3 2024, compared to $3.3 million in the same period of 2023, driven by strategic partnerships.

Early data from a Phase 2b/3 trial of izokibep in Hidradenitis Suppurativa (HS) shows improvement in draining tunnels in two-thirds of patients by week 4.

PepGen's PGN-EDO51 Phase 2 study shows promising initial data with mean exon skipping in biceps tissue of 2.15% at week 13 for Duchenne muscular dystrophy.

89bio is progressing pegozafermin, a FGF21 analog, through Phase 3 trials for metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG).

Revelation Biosciences secured Nasdaq continued listing, contingent on maintaining a $1.00 stock price by February 14, 2025.

Clearside Biomedical anticipates primary data readout from its Phase IIb ODYSSEY trial of CLS-AX for wet AMD in Q3 2024, assessing its potential as a maintenance therapy.

Axsome Therapeutics reported Q1 2024 total net product revenue of $75 million, marking a 160% year-over-year growth, driven by strong performance of its marketed products.

IDEAYA Biosciences focuses on precision medicine in oncology, leveraging molecular diagnostics to develop targeted therapies for specific patient populations.

Quoin Pharmaceuticals expands its Netherton Syndrome (NS) clinical trials to include two new sites in the United Kingdom.

Lipigon Pharmaceuticals has appointed Johan Liwing as its new CEO, effective December 16, 2024, bringing extensive experience from the life science industry.

Actimab-A has been granted orphan designation in the European Union by the EMA for treating newly diagnosed AML patients over 60 ineligible for standard induction therapy.

Shuttle Pharmaceuticals has successfully dosed the first three patients in a Phase 2 trial of ropidoxuridine for glioblastoma.

The FDA has granted early approval to Revuforj (revumenib) for specific acute leukemias, a significant milestone for Syndax Pharmaceuticals.

Eagle Pharmaceuticals has entered into a $69 million royalty purchase agreement with Blue Owl Capital to sell its royalty interest in BENDEKA, a treatment for chronic lymphocytic leukemia and non-Hodgkin lymphoma.

Petros Pharmaceuticals has successfully launched an AI tool integrated into its web app for patient self-screening, aiming to optimize the safe use of Stendra.

Glenmark Pharmaceuticals' US arm has launched Phytonadione Injectable Emulsion USP, 10mg/ml, a treatment for blood clotting problems caused by Vitamin K deficiency. The drug is bioequivalent and therapeutically equivalent to Hospira's Vitamin K Injectable Emulsion. Additionally, Glenmark reported promising Phase 1 clinical trial results for its Trispecific TREAT Antibody, ISB 2001, in treating Multiple Myeloma.

Cybin Inc. highlights positive Phase 2 data for CYB003, showing significant efficacy in treating major depressive disorder (MDD).

Minghui Pharmaceutical's MHB018A demonstrated positive topline results in a Phase Ib/II trial for active, moderate-to-severe Thyroid Eye Disease (TED).

Tonix Pharmaceuticals participated in the RECOVER Treating Long COVID workshop, discussing clinical trial endpoints for potential therapeutics.

Mirum Pharmaceuticals is making significant progress with its late-stage pipeline, including two investigational treatments for liver diseases. Volixibat, an IBAT inhibitor, is under evaluation in Phase 2 studies for primary sclerosing cholangitis and primary biliary cholangitis, and has received Breakthrough Therapy Designation. Additionally, chenodiol has shown positive results in a Phase 3 clinical study for CTX treatment, with a new drug application submitted to the FDA.